Literature DB >> 28204519

Cost-effectiveness of 'immediate IVF' versus 'delayed IVF': a prospective study.

M J C Eijkemans1,2, F A M Kersten3, A M E Lintsen3, C C Hunault2,4, C A M Bouwmans5, L Hakkaart-van Roijen5, J D F Habbema2, D D M Braat3.   

Abstract

STUDY QUESTION: How does the cost-effectiveness (CE) of immediate IVF compared with postponing IVF for 1 year, depend on prognostic characteristics of the couple? SUMMARY ANSWER: The CE ratio, i.e. the incremental costs of immediate versus delayed IVF per extra live birth, is the highest (range of €15 000 to >€60 000) for couples with unexplained infertility and for them depends strongly on female age and the duration of infertility, whilst being lowest for endometriosis (range 8000-23 000) and, for such patients, only slightly dependent on female age and duration of infertility. WHAT IS KNOWN ALREADY: A few countries have guidelines for indications of IVF, using the diagnostic category, female age and duration of infertility. The CE of these guidelines is unknown and the evidence base exists only for bilateral tubal occlusion, not for the other diagnostic categories. STUDY DESIGN, SIZE, DURATION: A modelling approach was applied, based on the literature and data from a prospective cohort study among couples eligible for IVF or ICSI treatment, registered in a national waiting list in The Netherlands between January 2002 and December 2003. PARTICIPANTS/MATERIALS, SETTING,
METHODS: A total of 5962 couples was included. Chances of natural ongoing pregnancy were estimated from the waiting list observations and chances of ongoing pregnancy after IVF from follow-up data of couples with primary infertility that began treatment. Prognostic characteristics considered were female age, duration of infertility and diagnostic category. Costs of IVF were assessed from a societal perspective and determined on a representative sample of patients. A cost-effectiveness comparison was made between two scenarios: (I) wait one more year and then undergo IVF for 1 year and (II) immediate IVF during 1 year, and try to conceive naturally in the following year. Comparisons were made for strata determined by the prognostic factors. The final outcome was a live birth. MAIN RESULTS AND THE ROLE OF CHANCE: The gain in live birth rate of the immediate IVF scenario versus postponed IVF increased with female age, and was independent from diagnostic category or duration of infertility. By contrast, the corresponding increase in costs primarily depended on diagnostic category and duration of infertility. The lowest CE ratio was just below €10 000 per live birth for endometriosis from age 34 onwards at 1 year duration. The highest CE ratio reached €56 000 per live birth for unexplained infertility at age 30 and 3 years duration, dropping to values below € 30 000 per live birth from age 32 onwards. It reached values below €20 000 per live birth with 3 years duration at age 34 and older. The CE ratio was in between for the three other diagnostic categories (i.e. Male infertility, Hormonal and Immunological/Cervical). LIMITATIONS, REASONS FOR CAUTION: We applied estimates of chances with IVF, excluding frozen embryos, for which we had no data. Therefore, we do not know the effect of frozen embryo transfers on the CE. WIDER IMPLICATIONS OF THE
FINDINGS: The duration of infertility at which IVF becomes cost-effective depends, firstly, on the level of society's willingness to pay for one extra live birth, and secondly, given a certain level of willingness to pay, on the woman's age and the diagnostic category. In current guidelines, the chances of a natural conception should always be taken into account before deciding whether to start IVF treatment and at which time. STUDY FUNDING/COMPETING INTEREST(S): Supported by Netherlands Organisation for Health Research and Development (ZonMW, grant 945-12-013). ZonMW had no role in designing the study, data collection, analysis and interpretation of data or writing of the report. Competing interests: none.
© The Author 2017. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com

Entities:  

Keywords:  IVF/ICSI; cost-effectiveness; expectant management; natural pregnancy; prediction models

Mesh:

Year:  2017        PMID: 28204519     DOI: 10.1093/humrep/dex018

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  7 in total

1.  Endometrial scratch to increase live birth rates in women undergoing first-time in vitro fertilisation: RCT and systematic review.

Authors:  Mostafa Metwally; Robin Chatters; Clare Pye; Munya Dimairo; David White; Stephen Walters; Judith Cohen; Tracey Young; Ying Cheong; Susan Laird; Lamiya Mohiyiddeen; Tim Chater; Kirsty Pemberton; Chris Turtle; Jamie Hall; Liz Taylor; Kate Brian; Anya Sizer; Helen Hunter
Journal:  Health Technol Assess       Date:  2022-01       Impact factor: 4.014

2.  Time as an outcome measure in fertility-related clinical studies: long-awaited.

Authors:  Sesh K Sunkara; Wenjing Zheng; Thomas D'Hooghe; Salvatore Longobardi; Jacky Boivin
Journal:  Hum Reprod       Date:  2020-08-01       Impact factor: 6.918

3.  Economic evaluation of endometrial scratching before the second IVF/ICSI treatment: a cost-effectiveness analysis of a randomized controlled trial (SCRaTCH trial).

Authors:  N E van Hoogenhuijze; R van Eekelen; F Mol; I Schipper; E R Groenewoud; M A F Traas; C A H Janssen; G Teklenburg; J P de Bruin; R H F van Oppenraaij; J W M Maas; E Moll; K Fleischer; M H A van Hooff; C H de Koning; A E P Cantineau; C B Lambalk; M Verberg; A M van Heusden; A P Manger; M M E van Rumste; L F van der Voet; Q D Pieterse; J Visser; E A Brinkhuis; J E den Hartog; M W Glas; N F Klijn; M van der Zanden; M L Bandell; J C Boxmeer; J van Disseldorp; J Smeenk; M van Wely; M J C Eijkemans; H L Torrance; F J M Broekmans
Journal:  Hum Reprod       Date:  2022-01-28       Impact factor: 6.918

4.  International Natural Procreative Technology Evaluation and Surveillance of Treatment for Subfertility (iNEST): enrollment and methods.

Authors:  Joseph B Stanford; Tracey Parnell; Kristi Kantor; Matthew R Reeder; Shahpar Najmabadi; Karen Johnson; Iris Musso; Hanna Hartman; Elizabeth Tham; Ira Winter; Krzysztof Galczynski; Anne Carus; Amy Sherlock; Jean Golden Tevald; Maciej Barczentewicz; Barbara Meier; Paul Carpentier; Karen Poehailos; Robert Chasuk; Peter Danis; Lewis Lipscomb
Journal:  Hum Reprod Open       Date:  2022-08-09

5.  Cost-effectiveness of medically assisted reproduction or expectant management for unexplained subfertility: when to start treatment?

Authors:  R van Eekelen; M J Eijkemans; M Mochtar; F Mol; B W Mol; H Groen; M van Wely
Journal:  Hum Reprod       Date:  2020-09-02       Impact factor: 6.918

Review 6.  Growing body of evidence supports intrauterine insemination as first line treatment and rejects unfounded concerns about its efficacy, risks and cost effectiveness.

Authors:  Gulam Bahadur; Roy Homburg
Journal:  JBRA Assist Reprod       Date:  2019-01-31

7.  Expectant Management Before In vitro Fertilization in Women Aged 39 or Above and Unexplained Infertility Does Not Decrease Live Birth Rates Compared to Immediate Treatment.

Authors:  Andrea Roberto Carosso; Rik van Eekelen; Alberto Revelli; Stefano Canosa; Noemi Mercaldo; Ilaria Stura; Stefano Cosma; Carlotta Scarafia; Chiara Benedetto; Gianluca Gennarelli
Journal:  Reprod Sci       Date:  2021-11-01       Impact factor: 2.924

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.